Questions remain about who will get monoclonal antibodies for COVID-19 preexposure prophylaxis
R Rubin - Jama, 2022 - jamanetwork.com
“AZD7442, AZD7442, AZD7442.” He finally hit pay dirt December 8, when hediscoveredthattheUSFoodandDrugAdmi…
had authorized AstraZeneca's long-acting monoclonal antibody combination, AZD7442
(Evusheld), for COVID-19 preexposure prophylaxis in adults and children at least 12 years
old who don't have an adequate immune response to COVID-19 vaccination or can't be fully
vaccinated. Although the FDA has authorized other companies' monoclonal antibody
products for COVID-19 postexposure prophylaxis and for the treatment of mild to moderate …
had authorized AstraZeneca's long-acting monoclonal antibody combination, AZD7442
(Evusheld), for COVID-19 preexposure prophylaxis in adults and children at least 12 years
old who don't have an adequate immune response to COVID-19 vaccination or can't be fully
vaccinated. Although the FDA has authorized other companies' monoclonal antibody
products for COVID-19 postexposure prophylaxis and for the treatment of mild to moderate …
